BioCardia, Inc. (OTC Pink: BCDA) is engaged in the production, development, and marketing of regenerative therapeutics and medications. The regenerative disease company is seeing shares soar 17.86% through early trading on Thursday, December 29, 2016. Over the past three months, BioCardia, Inc. has seen average daily volume of 542,565 shares. However, volume of 360,650 shares or dollar volume of $357,043, has already exchanged hands through early trading on Thursday.

Shares of BioCardia, Inc. are rallying today, after the company announced that its CardiAMP Heart Failure trial is slated to begin. The study will include up to 260 patients across 40 clinical sites. Specifically, the trials will take place within the Johns Hopkins University and the University of Florida at Gainesville systems. Here is the full press release detailing of the clinical trials:

BioCardia, Inc. Press Release:

SAN CARLOS, Calif.–(BUSINESS WIRE)–BioCardia®, Inc. [OTC:BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced the initiation of the CardiAMP Heart Failure pivotal trial, a randomized, controlled, multi-center study of up to 260 patients evaluating CardiAMP cell therapy at up to 40 clinical sites in the United States.

The trial has been initiated at two world-class centers: Johns Hopkins University, under the leadership of Dr. Peter Johnston and Dr. Gary Gerstenblith, and the University of Florida at Gainesville, under the leadership of Dr. David Anderson and Dr. Carl Pepine.

“We are honored to be working with the leading clinical research teams at each of these important centers to advance a therapeutic strategy that has great promise to help patients suffering from heart failure developed after a heart attack,” said Eric Duckers, MD, BioCardia Chief Medical Officer.

The CardiAMP Therapy for heart failure integrates a biomarker panel, a cell processing system for autologous bone marrow-derived cells, and a unique transendocardial delivery system. This therapy will be reviewed under the PMA regulations by the FDA’s Center for Biologics Evaluation and Research (CBER) division. More information is available at, trial identifier: NCT02438306.

About BioCardia, Inc.:

BioCardia, Inc., headquartered in San Carlos, CA, is developing regenerative biologic therapies to treat cardiovascular disease. CardiAMP® and CardiALLO® cell therapies are the company’s biotherapeutic product candidates in clinical development. The Company’s current products include the Helix™ transendocardial delivery system and the Morph® steerable guide and sheath catheter portfolio. BioCardia also partners with other biotherapeutic companies to provide its Helix systems and clinical support to their programs studying therapies for the treatment of heart failure, chronic myocardial ischemia and acute myocardial infarction.

Add a Comment to this Post